About
I. Research Rationale
Recent studies indicate that haemophagocytic lymphohistiocytosis (HLH) functions as an early warning signal of an inborn error of immunity rather than representing a single, discrete disease entity. Current understanding of penetrance and phenotypic spectra for HLH-associated genes relies on clinically ascertained cohorts, inflating risk estimates due to ascertainment bias. We aim at deriving unbiased penetrance estimates and gene-environment maps for HLH variants while testing whether immune co-mutations heighten expressivity.
II. Questions
1. What is the true population penetrance of pathogenic/likely pathogenic variants in familial HLH genes?
2. Do HLH gene variants predispose to non-classical phenotypes (e.g., lymphoma, autoimmune disorders)?
3. How do digenic architectures and environmental triggers (e.g., EBV) modulate expressivity?
4. Do patients harboring HLH-associated genetic mutations concurrently carry other immune-related genetic mutations? Does such co-occurrence lead to a higher penetrance?
III. Methodology
1. Penetrance quantification: Identify carriers of pathogenic variants in familial HLH-related genes ; Calculate age-dependent penetrance using survival analysis (time-to-HLH or related phenotype emergence)
2. Phenotype expansion analysis: Associate variants with 72 predefined ICD-10 codes (HLH, neuroinflammation, lymphoma, etc.) via logistic regression
3. Risk stratification modeling: Develop gene/variant-specific hazard ratio; Test digenic and polygenic risk score ; Integrate serological data (EBV IgG) as covariate.
4. Compare the frequency of immunoregulatory gene variants between carriers of HLH-related mutations and non-carriers using Fisher's exact test or logistic regression to identify significantly co-occurrent variants.